Aytu BioPharma's EPS increased by 71% in three years, but shareholders experienced a 97% loss. Shareholders can address concerns at the upcoming AGM on June 26, including CEO compensation.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing